Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study
In cancer-associated VTE, apixaban was associated with similar risks of recurrent VTE and major bleeding, and a lower risk of clinically relevant non-major bleeding compared with rivaroxaban. These findings suggest apixaban may be a favorable option for anticoagulation in cancer-associated VTE when minimizing bleeding risk is a priority.
Authors
- Jodi B Segal (ORCID: https://orcid.org/0000-0003-3978-9662)
- Hemalkumar B. Mehta (ORCID: https://orcid.org/0000-0001-9134-6370)
- G. Caleb Alexander (ORCID: https://orcid.org/0000-0002-5622-2986)
- Jingjing Sun (ORCID: https://orcid.org/0009-0008-7951-6267)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1371/journal.pmed.1004754
- Citations
- 1
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.87